Cowen, Barclays and ROTH all host healthcare conferences next week;
• Intellia Therapeutics (NASDAQ:NTLA) initiated with Outperform rating and $76 (158% upside) price target at JMP Securities.
• CRISPR Therapeutics (NASDAQ:CRSP) initiated with Outperform rating and $69 (34% upside) price target at JMP.
With this, I’ll likely hold my Crispr theme options (EDIT and NTLA) for a medium/long term instead.